Recent Postings to


Worst Pills, Best Pills Newsletter Articles

  View the entire February 2016 issue in PDF format

  • FDA Joins Hands With Industry to Weaken Its Own Rules
    (February 2016)
    Worst Pills, Best Pills News editor Dr. Michael Carome expresses outrage over disclosures that senior Food and Drug Administration representatives colluded with a leading medical device trade association in writing legislation that would weaken regulatory standards for medical devices.
  • St. John’s Wort: No ‘Wonder Remedy’ for Depression
    (February 2016)
    St. John’s wort, an over-the-counter herbal supplement, has been around for centuries, and many patients have been using it in recent years to self-medicate for depression. In this article, we explain why St. John’s wort should not be used to treat this disease.
  • Commonly Used Gout, Kidney Stone Drug Too Dangerous for Unproven Uses
    (February 2016)
    Allopurinol (LOPURIN, ZYLOPRIM) is an appropriate first-choice drug for treating gout and kidney stones caused by excess uric acid levels in the blood or urine. But you should not use allopurinol to treat high blood uric acid levels if you don’t have these disorders. Read this article to learn why.
  • Drugs That Cause Loss of Bladder Control
    (February 2016)
    Urinary incontinence, or loss of bladder control, is a common and often embarrassing problem that can have a huge impact on quality of life. Find out which drugs can cause this problem.
  • News Brief for February 2016
    (February 2016)
    In our news brief this month, we report on two recent warnings issued by the Food and Drug Administration about the diabetes drugs known as SGLT2 inhibitors, more commonly known as “flozins.” This family of drugs, all designated as Do Not Use, includes canagliflozin (INVOKAMET, INVOKANA), dapagliflozin (FARXIGA) and empagliflozin (JARDIANCE).
  • Still No Good Evidence That Nonstatin Drugs Prevent Heart Attacks and Strokes
    (February 2016)
    Statins have long been a mainstay of treatment for patients with high LDL (“bad” cholesterol) and cardiovascular disease. In this article, we explain why you should avoid combining a nonstatin cholesterol-lowering dug with a statin.

  View the entire January 2016 issue in PDF format

  • New Evidence That Off-Label Drug Use Increases Risk of Harm
    (January 2016)
    Worst Pills, Best Pills News editor Dr. Michael Carome discusses the implications of new research showing that patients taking prescription drugs for uses not approved by the Food and Drug Administration are more likely to suffer adverse reactions.
  • Health Canada Warns of Dangerous Drug Interaction
    (January 2016)
    Learn why Health Canada, an agency similar to the Food and Drug Administration, warned Canadian consumers not to combine repaglinide-containing diabetes medications (PRANDIN or PRANDIMET) with the anti-platelet drug clopidogrel (PLAVIX).
  • Questions & Answers
    (January 2016)
    In this month’s Questions & Answers feature, we address readers’ questions about using several non-traditional treatments for osteoarthritis pain, including cetyl myristoleate, s-adenosylmethionine or SAMe, and aloe vera.
  • Drug Treatments for Chronic Heart Failure
    (January 2016)
    For the approximately 5 million Americans suffering from chronic heart failure, there is a wide array of lifesaving drug treatments. Find out our take on the most recent expert guidelines for treating this disease.
  • Omega-3 Fatty Acid, Antioxidant Supplements Useless for Improving Cognitive Function
    (January 2016)
    In this article, we review results from a well-designed clinical trial funded by the National Institutes of Health that debunks the cognitive health claims for dietary supplements containing omega-3 fatty acids or the antioxidants lutein and zeaxanthin.
  • Dangers of Post-Surgery Delay in Resuming Blood Pressure Drugs
    (January 2016)
    Patients taking drugs to treat high blood pressure often are directed to stop their medication at least 24 hours before surgery. Learn why restarting these medications as soon as possible after surgery could save your life.

  View the entire December 2015 issue in PDF format

  • Inhaled Insulin AFREZZA Ineffective, Can Damage Lungs
    (December 2015)
    Find out why this new form of insulin, which is inhaled as a powder, is a dangerous alternative to injected forms of insulin and never should have been approved by the Food and Drug Administration for the treatment of diabetes.
  • Outrage Over Price Gouging by Pharma Companies Reaches New Heights
    (December 2015)
    Worst Pills, Best Pills News editor Dr. Michael Carome examines the possible implications of the rising tide of public anger over the high prices charged by pharma¬ceutical companies in the U.S.
  • Dangerous Atypical Antipsychotics Minimally Effective for Depression
    (December 2015)
    Some powerful antipsychotic drugs originally developed to treat schizophrenia now have been approved to treat depression. Learn about the serious side effects of these drugs that make it advisable to explore other, safer options for managing depression.
  • Long-Acting Opioids: Extra Caution Needed
    (December 2015)
    In this article, we review new evidence suggesting that long-acting opioids are associated with a higher risk of unintentional life-threatening over¬doses than short-acting forms of these drugs.
  • Many Atrial Fibrillation Patients With Lowest Stroke Risk Receive Unnecessary Blood Thinners
    (December 2015)
    A recent study revealed that some cardiologists prescribe blood thinners to atrial fibrillation patients who don’t need them because their risk of stroke is very low. Read this article to learn who these patients are.
  • News Brief for December 2015
    (December 2015)
    In our news brief this month, we discuss Public Citizen's recent petition to the Food and Drug Administration to correct the labeling of a new drug approved for treatment of an uncommon sleep disorder in totally blind people. The agency mistakenly approved a label that expanded the drug's use to nonblind patients.

Additional Information from Public Citizen

Copyright © 2016 Public Citizen's Health Research Group. All rights reserved.